INTRODUCTION
Innate immunity plays a crucial role as a first line of defence against viral infections and it is characterized by being induced rapidly upon infection and by lacking memory and specificity (Biron & Sen, 2001) . Type I interferons (IFN-a/b) are major players in such protection and are expressed through a highly regulated transcriptional process in response to most intracellular infectious agents, especially viruses (Derbyshire, 1989; Biron & Sen, 2001 ). However, many viruses, including Porcine reproductive and respiratory syndrome virus (PRRSV), induce variable levels of proinflammatory cytokines and IFNs (Van Reeth et al., 1999 ), yet also have developed mechanisms to subvert the host innate immune response (Albina et al., 1998; Buddaert et al., 1998) .
PRRSV is considered one of the most important pathogens of swine and affects the industry adversely as a result of direct and indirect losses (reviewed by Rossow, 1998) . PRRSV has become distributed widely throughout the world and substantial efforts are ongoing to design rational and effective control strategies.
Whilst IFN-a constitutes an early host response to PRRSV (Chung et al., 2004) , there is mounting evidence that the virus circumvents the host innate response, resulting in an inadequate induction of type I IFNs (Albina et al., 1998; Buddaert et al., 1998 ; reviewed by Murtaugh et al., 2002) . As a consequence, there is a delayed production of IFN-c, cellular immunity and neutralizing antibodies (Royaee et al., 2004) , resulting in delayed viral clearance (Batista et al., 2004; Murtaugh et al., 2002; Xiao et al., 2004) . In a recent study, it was found that induction of type I IFN transcripts in cells by double-stranded RNA was inhibited significantly by exposure to PRRSV, suggesting that the virus may interfere with type I IFN at the transcriptional level (Miller et al., 2004) . However, in another study, it was shown that a PRRSV field isolate enhanced poly(IC)-induced IFN-a production strongly in porcine alveolar macrophages (PAMs), but this priming effect was inhibited by other PRRSV isolates . These authors suggested that inhibition of IFN-a production occurs by inhibiting host protein synthesis. Clearly, additional work is needed to determine the role of viral proteins in controlling the host innate response. Considering that infection with PRRSV results in a poor type I IFN induction (IFN-a), suppression of innate immunity may be a mechanism that could explain, at least in part, the peculiarities of the host response to PRRSV. However, there appears to be a high level of variability between PRRSV field isolates in their sensitivity and capacity to induce or suppress IFN-a production . These differences may account for differences in virulence and pathogenicity of PRRSV strains.
The mechanisms of protective immunity against PRRSV are not understood completely, although there appears to be a consensus that both neutralizing antibody and cellular immunity are required for protection. Despite a high variability between animals, a strong cellular immunity, as measured by IFN-c ELISPOTs, appeared to correlate with protection from PRRSV (Lowe et al., 2005) . Another study showed that treatment with interleukin-12 (IL-12) resulted in lower virus titres in lungs of infected pigs, which also correlated with higher in vitro levels of IFN-c and lower levels of IL-10 produced by PAMs from treated animals (Carter & Curiel, 2005) . Furthermore, the application of either IL-12 or IFN-a resulted in higher IFN-c levels, although this did not necessarily result in a lower viraemia (Meier et al., 2004) . However, in an earlier study, inoculation of pigs with porcine respiratory coronavirus, a potent inducer of IFN-a, provided protection from a subsequent PRRSV infection, as shown by a significant reduction in virus titres in lungs (Buddaert et al., 1998) . Moreover, a recent study demonstrated that PAMs infected dually with Porcine circovirus-2 (PCV-2) and PRRSV resulted in reduced cytopathic effects (CPE) compared with infection with only PRRSV (Chang et al., 2005) . The infection with PCV-2 appeared to override the inhibition of IFN-a induction by PRRSV, as higher levels of IFN-a were detected in dually PCV-2/PRRSV-infected PAMs. Together, the data support an important role for type I IFNs in the initial innate response and the subsequent activation of adaptive immunity.
We have previously constructed a replication-defective human adenovirus type 5 (Ad5) vector containing the swine IFN-b gene (Ad5-swIFN-b) and demonstrated high levels of expression of biologically active IFN-b protein in IBRS-2 (swine kidney) cells (Chinsangaram et al., 2003) . Interestingly, the Ad5 vector coding for porcine IFN-a protected pigs completely from challenge with Foot-andmouth disease virus (FMDV) (Chinsangaram et al., 2003) and partially protected cattle from challenge with the same virus (Wu et al., 2003) .
The present study was conducted to examine the ability of swIFN-b to neutralize PRRSV in vitro as a step towards understanding its possible antiviral role in vivo. (Chinsangaram et al., 2003; Moraes et al., 2001) .
Swine IFN-b. Ad5-swIFN-b was used to generate swIFN-b by infection of 293 cells. Culture supernatants from HEK 293 cells infected with Ad5-Blue served as the control in the assays. Briefly, Ad5-swIFN-b-and Ad5-Blue-infected 293 cells were processed 48-72 h post-infection as follows: cells and culture supernatants were clarified twice by low-speed centrifugation (300 g) in a Beckman TH-4 rotor. The resulting supernatants were centrifuged at 28 000 r.p.m. for 2 h to pellet the virus. The supernatants were then acidified (pH 2.0) for 18 h at 4 uC and adjusted to pH 7.2 for use in the assays.
Antiviral swIFN-b tests. The antiviral activity of swIFN-b against PRRSV was tested on MARC-145 cells or PAMs. In general, two criteria were used to measure the antiviral activity of swIFN-b: the presence or absence of CPE as an end point and a real-time RT-PCR as a quantitative test to measure the concentration of viral RNA in culture supernatants at different times post-inoculation. Occasionally, culture supernatants were also assayed for the presence of virus by titration on MARC-145 cells. For the antiviral tests, the cells were primed for 18-20 h with dilutions of Ad5-swIFN-b or control Ad5-Blue culture supernatants (control supernatants) processed as described above. The cells were then infected with PRRSV for 1.5-2.0 h, washed and replenished with Ad5-swIFN-b or Ad5-Blue supernatant. For detection of CPE, the cells were incubated for up to 7 days post-inoculation. In some experiments, supernatants from cells treated as described above were collected for titration of virus in MARC-145 cells. A comparison of the sensitivity to IFN-b was also performed with several strains of PRRSV. The specificity of the protection was determined by blocking swIFN-b with mAbs generated as described below.
Real-time RT-PCR. To quantify PRRSV RNA by real-time RT-PCR, Ad5-swIFN-b-or control supernatant-primed MARC-145 cells or PAMs were inoculated with virus for 1.5-2.0 h at 37 uC and then washed four times with serum-free medium, at which point a sample of supernatant for each treatment was collected as time 0. The cells were then replenished with the appropriate supernatants and incubated for an additional 72-96 h, and culture supernatants were sampled for real-time RT-PCR analysis. Briefly, viral RNA was extracted from supernatants with TRIzol LS (Invitrogen) following the manufacturer's protocol. RNA pellets were suspended in 50 ml DEPC-treated water and a reverse transcription (RT) reaction was performed by utilizing an RT reaction kit (Applied Biosystems), 10 ml RNA and a PRRSV open reading frame 7 (ORF-7)-specific RT primer (ORF7 RT, 59-TCGCCCTAAT-39). Two ORF-7-specific primers were designed to amplify a 200 bp fragment in the conserved ORF-7 region by utilizing the DNAMan software (Real-time 7 F, 59-AATAACAACGGCAAGCAGCA-39; Real-time 7 R, 59-GCACAGT ATGATGCGTAGGC-39). Real-time PCR was performed by using SYBRGreen PCR master mix, 0.25 mM each primer and 2.5 ml of the RT reaction, following the manufacturer's protocol (Applied Biosystems). Samples were heated for 10 min at 94 uC and a threestep cycle (30 s at 94 uC, 30 s at 64 uC and 30 s at 72 uC) was repeated 40 times. A standard curve was generated with purified viral RNA derived from caesium chloride gradient-purified PRRSV and utilized to determine the viral RNA concentration in test samples. The viral RNA was quantified spectrophotometrically, aliquotted and stored at 280 uC for further use. Aliquots of the viral RNA were tested periodically to ensure integrity and consistency.
Monoclonal antibodies. A series of mAbs against swIFN-b was produced in our laboratory. Briefly, BALB/c mice were immunized with an expression vector carrying the swine IFN-b gene. Hybridomas were produced by using single spleen-cell suspensions from these mice and Sp2/0 myeloma cells by standard polyethylene glycol-mediated fusion. Clones were screened against Centricon-100-filtered, pH 2.0-treated and neutralized 293 cell-culture supernatants containing recombinant swIFN-b. Positive clones were expanded further and cloned by limiting dilution. Upon cloning two or three times, hybridoma fluids were retested to ensure reactivity against swIFN-b and the isotype was determined.
Affinity purification of swIFN-b. To purify swIFN-b, affinity columns were developed with monoclonal anti-swIFN-b antibodies. For this purpose, an anti-swIFN-b mAb designated 10E9 (IgG2b), developed in our laboratory, was purified from hybridoma culture fluids on Sepharose-anti-mouse IgG or Sepharose-protein A columns. The purified anti-swIFN-b mAb fractions were pooled and coupled to CNBr-activated Sepharose beads according to the instructions of the manufacturer (Pharmacia) to generate a Sepharose-anti-swIFN-b matrix. The Sepharose-anti-swIFN-b matrix was packed in a column and utilized to fractionate swIFNb from culture fluids of HEK 293 cells infected with Ad5-swIFN-b (Moraes et al., 2001) . The bound swIFN-b was eluted with glycine/ HCl buffer (pH 2.5) and adjusted to pH 7.2 by immediate dialysis against PBS (pH 7.2). The fractions were acidified (to pH 2.0) overnight and adjusted to pH 7.2. The protein concentration of the fractions was quantified by spectrophotometry at a wavelength of 280 nm, then the fractions were aliquotted and frozen at 270 uC for further use.
RESULTS swIFN-b blocks virus replication in MARC-145 cells
The antiviral activity of swIFN-b produced in Ad5-swIFNb-infected HEK 293 cells was initially examined in MARC-145 cells, a cell line used routinely to propagate PRRSV (Kim et al., 1993) . Briefly, culture supernatants from HEK 293 cells infected with either Ad5-swIFN-b or control Ad5-Blue, treated as described above, were incubated overnight with MARC-145 cells and then infected with PRRSV strain Mo8981. Cells lacking swIFN-b and inoculated with virus (virus control) or cells without swIFN-b or virus (cell control) were included. Cells treated with Ad5-swIFN-b and infected with PRRSV did not develop CPE, whereas cells treated with control supernatants developed CPE (Table 1) . Protection was evident up to a dilution of 1 : 160 for swIFNb when using 30 TCID 50 per well, whereas CPE was recorded in cells even at the lowest dilution (1 : 5) of control supernatants at both high and low virus concentrations. These results are summarized in Table 1 and represent data from two or more similar tests using two separate preparations of Ad5-swIFN-b and control Ad5-Blue supernatants. The protective effects were dose-dependent, as shown by the decrease of antiviral activity at higher dilutions of swIFN-b versus the higher virus concentration (Table 1) . Similar results were obtained against FMDV using culture supernatants obtained from Ad5-swIFN-b-infected IBRS-2 cells (a swine cell line) (Chinsangaram et al., 2003) .
To quantify the effect of swIFN-b on PRRSV replication, we followed virus growth by real-time RT-PCR. MARC-145 cells treated with Ad5-swIFN-b supernatants had approximately 50-150-fold lower viral RNA loads at 72 h postinfection, compared with virus control or cell control supernatant-treated cells, respectively ( Table 2 ). Priming of MARC-145 cells with affinity-purified fractions of swIFN-b reduced the replication of PRRSV significantly, as demonstrated by the lower viral RNA loads detected 72 h postinfection compared with the virus control. The antiviral activity was dose-dependent, as it was reduced at higher dilutions of the purified fractions (Table 3 ). The antiviral activity was higher in fractions 2 and 3, indicating that these fractions contained the highest concentration of swIFN-b per unit of mass, as all of the affinity fractions were used at (Table 4 ). In contrast, the control supernatant-treated cells, which had visible CPE in earlier experiments, had a significant increase in virus RNA load 24 h post-infection (from 0 to 7.40 pg in 200 ml), comparable to that observed in the virus-infected control (from 0 to 9.60 pg in 200 ml) (Table 4) . At 48 h, viral RNA loads in the virus control increased to 20.8 pg in 200 ml and, for unknown reasons, the viral load of control supernatanttreated cells was only 1.9 pg in 200 ml. In clear contrast, the Ad5-swIFN-b-treated cells had viral RNA loads lower than 0.2 pg in 200 ml at both time points, which were at least 13 times lower than that detected with the control supernatant at 48 h and up to 140 times lower than that detected with the virus control at 48 h.
Antiviral effects of swIFN-b blocked by mAb to swIFN-b
The incubation of anti-swine IFN-b mAbs with swIFN-b prior to priming and infection of MARC-145 cells with PRRSV isolate Mo25544 resulted in inhibition of the antiviral activity. This was evident by the presence of CPE in the antibody-and IFN-treated cells, but not in control cells treated with the same amount of IFN and no antibody, which were protected fully from PRRSV infection (data not shown). As expected, CPE was also evident in the virus control and in cells primed with control supernatants and infected with PRRSV. To confirm these results, Ad5-swIFNb or control supernatants were diluted serially and incubated with a constant amount of antibody before priming and infection of cells. The results of the latter experiment, summarized in Table 5 and Fig. 1 , confirmed that the antiviral activity of swIFN-b was abolished specifically and significantly by one of the anti-swIFN-b mAbs (10E9, IgG2b) and partially by the other mAb (10F1, IgM). This was determined by the presence of CPE in the cells (Table 5 ) and significantly higher viral RNA loads in IFN-plus anti-IFN-primed cells, compared with cells primed with IFN reacted with isotype controls (Fig. 1) . Thus, compared with the isotype controls, there was an increase in viral RNA of 41-and 8.5-fold with 10E9, and 2.2-and 3.1-fold with 10F1 when 20 or 10 units of swIFN-b was used per well. The ratios were calculated after subtracting the viral RNA load detected with IFN alone.
Differential sensitivity of PRRSV isolates to swIFN-b
The sensitivity to swIFN-b varied among different isolates of PRRSV tested. Whilst two field isolates, Mo25544 and Mo8981, and a vaccine strain were clearly sensitive to swIFN-b, another isolate, PDV130 9301 (NVSL), was less sensitive (Table 6 ). The swIFN-b-sensitive isolates did not induce CPE in cells treated with IFN, and virus replication was undetectable in MARC-145 cells. These isolates replicated and induced CPE in cells treated with control Whilst the actual mechanism of protection conferred by exogenous swine IFN-b in either cell used in this study was not investigated, it is clear that it is capable of overriding PRRSV inhibition of type I IFN production reported in MARC-145 cells earlier (Miller et al., 2004; Lee et al., 2004) . Several mechanisms are probably involved in conferring such protection, as suggested with type II IFN (Bautista & Molitor, 1999; Rowland et al., 2001) . Our data suggest that the observed antiviral effects of swine IFN-b are not speciesspecific, as these occurred not only in PAMs, but also in MARC-145 cells, a primate cell line. This is consistent with an earlier study in which MARC-145 cells were protected from PRRSV infection by treatment with human IFN-c or IFN-a (Rowland et al., 2001 ).
The protection of alveolar macrophages conferred by swIFN-b in this study is significant and highly relevant, as these cells are the principal target cells for PRRSV (Rossow, 1998) . Therefore, the in vitro antiviral effects shown here should be verified in vivo to determine the actual significance of swIFN-b in protection of swine from PRRSV. PRRSV is no doubt an intriguing virus, due to its peculiar course of infection and development of a protective immune response. Evidence has accumulated showing that, upon infection with PRRSV, there is a poor induction of IFN-a, which appears to affect the ensuing adaptive immune responses critically, including delayed IFN-c and neutralizing-antibody production, ultimately leading to persistent infection (Albina et al., 1998; Buddaert et al., 1998; Royaee et al., 2004; Xiao et al., 2004) .
Data from a number of studies on the effect and role of IFNa in swine associate type I IFNs, primarily IFN-a, with an antiviral function . However, the sensitivity of PRRSV to IFN-a varied among different American field isolates, as did the ability to induce or suppress IFN-a production . Thus, the IFN-a-inducing or -suppressing phenotypes reflect virulence differences encountered in field isolates of PRRSV. Much less is known about the function and role of swIFN-b. We have tested the effect of swIFN-b against a few isolates of PRRSV and our data appear to be consistent with the variability in sensitivity of PRRSV isolates shown with IFN-a . For example, the two isolates from Missouri, Mo25544 and M08981, that were sensitive to swIFN-b in our study were also sensitive to IFN-a (S. B. Kleiboeker, personal communication). However, at this time, the basis for this differential effect with swIFN-b remains unknown. A more detailed molecular comparison between IFN-sensitive and -resistant PRRSV isolates is clearly needed to address this question, to identify what viral protein(s) is involved and to determine whether the differences are at the transcriptional or translational stages of IFN production . Recently Lee & Kleiboeker (2005) demonstrated that PRRSV infection activates nuclear factor kB (NF-kB), a transcription factor required for synthesis of type I IFN mRNAs. Therefore, the mechanism that PRRSV utilizes to limit type I IFN responses involves other steps in IFN gene activation. In addition, whether PRRSV isolates have a differential ability to induce IFN-b remains unknown. The poor IFN-a induction observed during infection with PRRSV (Albina et al., 1998; Lee et al., 2004) may be the result of an early inhibition of IFN-b induction mediated by the virus.
Our data clearly show an antiviral activity of swIFN-b in vitro. The actual role of swIFN-b in vivo has not been elucidated directly, but is presumably associated intimately with phases I and II of the innate immune response to pathogens and promoting and strengthening the linkage between innate and adaptive immunity. To test this assumption, we plan to perform challenge experiments using IFN-sensitive and -resistant PRRSV isolates in animals primed by inoculation with Ad5-swIFN-b and to measure the appropriate response end points, including protection. Overcoming the type I IFN suppression observed in PRRSVinfected animals (Albina et al., 1998; Buddaert et al., 1998) , now widely recognized in the pathogenesis of PRRS, may be key in the development of a timely adaptive response and control of the infection.
